U.S. Medical Eligibility Criteria for Contraceptive Use, 2024

The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of t...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Recommendations and reports 2024-08, Vol.73 (4), p.1-126
Main Authors: Nguyen, Antoinette T, Curtis, Kathryn M, Tepper, Naomi K, Kortsmit, Katherine, Brittain, Anna W, Snyder, Emily M, Cohen, Megan A, Zapata, Lauren B, Whiteman, Maura K
Format: Article
Language:English
Subjects:
Adolescent
Adult
Anticoagulants
Antiviral agents
Birth control
Breast feeding
Cardiomyopathy
Cardiovascular diseases
Chronic conditions
Cirrhosis
Contraception
Contraceptive Agents
Contraceptives
Contraindications
Criteria
Drug interaction
Eligibility Determination
Embolism
Family planning
Female
Health care
Heart diseases
Hepatocytes
HIV
Human immunodeficiency virus
Humans
Intrauterine devices
IUD
Kidney diseases
Liver cirrhosis
Liver diseases
Male
Methods
Oral contraceptives
Patient satisfaction
Patients
Progestin
Revisions
Sickle cell disease
Systemic lupus erythematosus
Thromboembolism
Thrombophilia
Thrombosis
United States
Vagina
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. MEC (CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR 2016:65[No. RR-3]:1-103). Notable updates include 1) the addition of recommendations for persons with chronic kidney disease; 2) revisions to the recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, high risk for HIV infection, cirrhosis, liver tumor, sickle cell disease, solid organ transplantation, and drug interactions with antiretrovirals used for prevention or treatment of HIV infection); and 3) inclusion of new contraceptive methods, including new doses or formulations of combined oral contraceptives, contraceptive patches, vaginal rings, progestin-only pills, levonorgestrel intrauterine devices, and vaginal pH modulator. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.
ISSN:1057-5987
1545-8601
1545-8601
DOI:10.15585/mmwr.rr7304a1